AU2017281589B2 - Microbial carotenoids affecting gut microbial composition - Google Patents

Microbial carotenoids affecting gut microbial composition Download PDF

Info

Publication number
AU2017281589B2
AU2017281589B2 AU2017281589A AU2017281589A AU2017281589B2 AU 2017281589 B2 AU2017281589 B2 AU 2017281589B2 AU 2017281589 A AU2017281589 A AU 2017281589A AU 2017281589 A AU2017281589 A AU 2017281589A AU 2017281589 B2 AU2017281589 B2 AU 2017281589B2
Authority
AU
Australia
Prior art keywords
carotenoids
microbial
gut
intestinal
carotenoid compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281589A
Other languages
English (en)
Other versions
AU2017281589A1 (en
Inventor
Selin BOLCA
Cindy DUYSBURGH
Massimo Marzorati
Iris PINHEIRO
Sam Possemiers
Pieter Van Den Abbeele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Resource Management Health NV MRM Health
Original Assignee
Microbial Resource Management Health NV MRM Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Resource Management Health NV MRM Health filed Critical Microbial Resource Management Health NV MRM Health
Publication of AU2017281589A1 publication Critical patent/AU2017281589A1/en
Assigned to MICROBIAL RESEARCH MANAGEMENT HEALTH NV reassignment MICROBIAL RESEARCH MANAGEMENT HEALTH NV Request for Assignment Assignors: PRODIGEST BVBA
Application granted granted Critical
Publication of AU2017281589B2 publication Critical patent/AU2017281589B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2017281589A 2016-06-22 2017-06-22 Microbial carotenoids affecting gut microbial composition Active AU2017281589B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16175832.1 2016-06-22
EP16175832 2016-06-22
PCT/EP2017/065348 WO2017220708A1 (en) 2016-06-22 2017-06-22 Microbial carotenoids affecting gut microbial composition

Publications (2)

Publication Number Publication Date
AU2017281589A1 AU2017281589A1 (en) 2019-01-31
AU2017281589B2 true AU2017281589B2 (en) 2023-03-23

Family

ID=56203217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017281589A Active AU2017281589B2 (en) 2016-06-22 2017-06-22 Microbial carotenoids affecting gut microbial composition

Country Status (12)

Country Link
US (1) US11324717B2 (enExample)
EP (1) EP3474862B1 (enExample)
JP (1) JP6966543B2 (enExample)
KR (1) KR102413408B1 (enExample)
CN (1) CN109641006B (enExample)
AU (1) AU2017281589B2 (enExample)
BR (1) BR112018076485A8 (enExample)
CA (1) CA3028031C (enExample)
IL (1) IL263683B (enExample)
MX (1) MX390386B (enExample)
RU (1) RU2759600C2 (enExample)
WO (1) WO2017220708A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949001A (zh) 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20190127710A (ko) * 2017-02-07 2019-11-13 캘리포니아 인스티튜트 오브 테크놀로지 헌팅톤병 및 레트 증후군에서의 장 미생물총의 조정
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
WO2020043797A1 (en) * 2018-08-29 2020-03-05 Dsm Ip Assets B.V. Formulations for improving gut health
CN110283754B (zh) * 2019-07-11 2021-02-02 中国科学院北京基因组研究所 用于类风湿关节炎炎症状态评估及预后评价的肠道微生物菌群
KR102369996B1 (ko) * 2020-04-21 2022-03-02 박선민 대사성 질환과 안질환의 예방 및 건강 유지를 위한 장내 미생물 검사 기반 맞춤형 프리바이오틱스 또는 프로바이오틱스 정보 제공방법
CN115606802A (zh) * 2022-10-21 2023-01-17 中国农业大学 番茄红素在制备修复肠屏障损伤的产品中的应用
WO2025262090A1 (en) 2024-06-18 2025-12-26 Dsm Ip Assets B.V. Combination of carotenoids and inulin and uses thereof
CN119184223A (zh) * 2024-10-14 2024-12-27 元医(杭州)科技有限公司 一种基于耐辐射奇球菌素的功能宠物食品及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066108A1 (en) * 2005-12-06 2007-06-14 Royal Holloway And Bedford New College Bacterial production of carotenoids
WO2012017199A1 (en) * 2010-08-03 2012-02-09 Royal Holloway And Bedford New College Et Al Fatty acid esters of carotenoid glucosides as colouring agents for foodstuffs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066108A1 (en) * 2005-12-06 2007-06-14 Royal Holloway And Bedford New College Bacterial production of carotenoids
WO2012017199A1 (en) * 2010-08-03 2012-02-09 Royal Holloway And Bedford New College Et Al Fatty acid esters of carotenoid glucosides as colouring agents for foodstuffs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PEREZ-FONS L. et al.: "Identification and the developmental formation of carotenoid pigments in the yellow/orange Bacillus spore-formers", BIOCHIMICA ET BIOPHYSICA ACTA, 2011, vol. 1811, pp. 177-185, doi:10.1016/j.bbalip.2010.12.009 *
SHINDO K. et al.: "Methyl Glucosyl-3,4-dehydro-apo-8'-lycopenoate, a Novel Antioxidative Glyco-C30-carotenoic Acid Produced by a Marine Bacterium Planococcus maritimus", JOURNALOF ANTIBIOTICS, 2008, vol. 61, no. 12, pp. 729-735 *
SY C. et al.: "Interactions between Carotenoids from Marine Bacteria and Other Micronutrients: Impact on Stability and Antioxidant Activity", Marine Drugs, 2015, vol. 13, pp. 7020-7039, doi:10.3390/md13117020 *

Also Published As

Publication number Publication date
RU2019101481A3 (enExample) 2020-10-16
BR112018076485A2 (pt) 2019-04-09
JP2019524877A (ja) 2019-09-05
IL263683B (en) 2022-04-01
KR20190039687A (ko) 2019-04-15
US20190209516A1 (en) 2019-07-11
US11324717B2 (en) 2022-05-10
KR102413408B1 (ko) 2022-06-27
RU2759600C2 (ru) 2021-11-16
BR112018076485A8 (pt) 2022-12-06
MX2018016118A (es) 2019-07-08
WO2017220708A1 (en) 2017-12-28
CA3028031C (en) 2023-02-28
JP6966543B2 (ja) 2021-11-17
RU2019101481A (ru) 2020-07-22
CN109641006A (zh) 2019-04-16
EP3474862A1 (en) 2019-05-01
CN109641006B (zh) 2022-07-01
AU2017281589A1 (en) 2019-01-31
CA3028031A1 (en) 2017-12-28
MX390386B (es) 2025-03-20
EP3474862B1 (en) 2025-10-29
IL263683A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CA3028031C (en) Microbial carotenoids affecting gut microbial composition
Bomba et al. Improvement of the probiotic effect of micro-organisms by their combination with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids
Klinder et al. Fecal water genotoxicity is predictive of tumor-preventive activities by inulin-like oligofructoses, probiotics (Lactobacillus rhamnosus and Bifidobacterium lactis), and their synbiotic combination
Abbasi et al. Postbiotics: science, technology and applications
US11260087B2 (en) Composition for preventing or treating menopause, containing Lactobacillus acidophilus
BR112012008005B1 (pt) composição compreendendo cepas de lactobacillus plantarum
US12016890B2 (en) Composition for preventing or treating menopause, containing Lactobacillus intestinalis
WO2023066973A1 (en) Probiotic strains for reducing blood cholesterol and/or treating dyslipidemia, and methods for using and producing the same
Li et al. Dietary pectin attenuates Salmonella typhimurium-induced colitis by modulating the TLR2-NF-κB pathway and intestinal microbiota in mice
Park et al. Combining 2′-fucosyllactose and galacto-oligosaccharides exerts anti-inflammatory effects and promotes gut health
Enespa et al. Synbiotics in Nutrition
da FONSECA et al. The function of nutraceuticals in the intestinal modulation of animals with non-alcoholic steatohepatitis: a systematic review.
Borgonovi Biocompostos de buriti e maracujá: perfil, aplicação em leite fermentado probiótico e modulação da microbiota in vitro
Minuto From youth to old age: therapeutic potential of microbiota interventions in the gut-brain-axis
Yao et al. Effect of microencapsulated Lactobacillus plantarum LIP-1 on cholesterol metabolism in hyperlipidaemic rats
Khalid Hammad Shoukr et al. The Effect of Synbiotic Dietary Supplementation on the Lipid Profile and Liver Functions of Hyperlipidemia in Rats
EP4619019A1 (en) Compositions
EA049899B1 (ru) Штаммы бактерий, их композиции и их применение в способах лечения дефицита витамина d и связанных с ним расстройств
Soleymanzadeh et al. Does Probiotic Therapy Have Effect on Serum Calcium and Cholesterol Levels in Demyelinated Hippocampus?
WO2025262090A1 (en) Combination of carotenoids and inulin and uses thereof
Moghadam et al. Does Probiotic Therapy Have Effect on Serum Calcium and Cholesterol Levels in Demyelinated Hippocampus?

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MICROBIAL RESEARCH MANAGEMENT HEALTH NV

Free format text: FORMER APPLICANT(S): PRODIGEST BVBA

FGA Letters patent sealed or granted (standard patent)